Main content

    Head and Neck Cancer Clinical Trials

    CPMC Cancer Services

    Oncology / Cancer Clinical Trials Main Page | Adult Clinical Trials Main Page

    Further protocol information can be found on the links below at ClinicalTrials.gov


    Active Trials

    Title: Randomized Phase II/III Trial of Surgery and Postoperative Radiation Delivered With Concurrent Cisplatin Versus Docetaxel Versus Docetaxel and Cetuximab for High-Risk Squamous Cell Cancer of the Head and Neck
    Description: This randomized phase II/III trial studies how well radiation therapy works when given together with cisplatin compared to docetaxel or cetuximab and docetaxel after surgery in treating patients with stage III-IV squamous cell head and neck cancer
    Investigator: NCI - National Cancer Institute
    Eligibility: Subjects, 18 y/o and older, with a pathologically (histologically or cytologically) proven diagnosis of head and neck squamous cell carcinoma (HNSCC) involving the oral cavity (excluding lips), oropharynx (p16 negative), larynx, or hypopharynx within 63 days of registration
    Status: Please contact site for study status
    Contact: Peter Gasper, 415-600-3472, Email: GasperJP@cpmcri.org about Study RTOG 1216

    Title: Randomized Phase II and Phase III Studies of Individualized Treatment for Nasopharyngeal Carcinoma Based on Biomarker Epstein Barr Virus (EBV) Deoxyribonucleic Acid (DNA)
    Description: Individualized Treatment in Treating Patients With Stage II-IVB Nasopharyngeal Cancer Based on EBV DNA
    Investigator: NCI - National Cancer Institute
    Eligibility: Subjects, 18 y/o and older, with a biopsy proven (from primary lesion and/or lymph nodes) diagnosis of cancer of the nasopharynx
    Status: Please contact site for study status
    Contact: Peter Gasper, 415-600-3472, Email: GasperJP@cpmcri.org about Study NRG HN001

    Title: A Phase III Study of Postoperative Radiation Therapy (IMRT) +/- Cetuximab for Locally-Advanced Resected Head and Neck Cancer
    Description: This randomized phase III trial is studying radiation therapy to see how well it works compared with radiation therapy given together with cetuximab in treating patients who have undergone surgery for locally advanced head and neck cancer
    Investigator: NCI - National Cancer Institute
    Eligibility: Subjects, 18 y/o and older, with a histologically confirmed squamous cell carcinoma (including variants, such as verrucous carcinoma, spindle cell carcinoma, or carcinoma not otherwise specified) of the head and neck
    Status: Please contact site for study status
    Contact: Peter Gasper, 415-600-3472, Email: GasperJP@cpmcri.org about Study RTOG 0920

    Title: A Randomized Phase II Trial for Patients With p16 Positive, Non-smoking Associated, Locoregionally Advanced Oropharyngeal Cancer
    Description: This randomized phase II trial studies how well modestly reduced-dose intensity-modulated radiation therapy (IMRT) with or without cisplatin works in treating patients with advanced oropharyngeal cancer
    Investigator: NCI - National Cancer Institute
    Eligibility: Subjects, 18 y/o and older, with a pathologically (histologically or cytologically) proven diagnosis of squamous cell carcinoma (including the histological variants papillary squamous cell carcinoma and basaloid squamous cell carcinoma) of the oropharynx (tonsil, base of tongue, soft palate, or oropharyngeal walls)
    Status: Please contact site for study status
    Contact: Peter Gasper, 415-600-3472, Email: GasperJP@cpmcri.org about Study NRG HN002

    • updated March 2015

    Back to top